Drugs / ROVANERSEN
ROVANERSEN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04617847 | Apr 2020 → May 2021 | Huntington disease | Wave Life Sciences USA, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03225833 | Jul 2017 → May 2021 | Huntington disease | Wave Life Sciences USA, Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROVANERSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650526 ↗ |
| Known as | BMTR-5150 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650526 ↗ |
| Known as | WV-1092 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650526 ↗ |
| Known as | WVE-120101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03225833 ↗ |
| Modality | Antisense oligonucleotide | “stereopure antisense oligonucleotide (ASO)” NCT03225833 ↗ |
| Route | Intrathecal | “WVE-120101 Administered Intrathecally” NCT03225833 ↗ |